Background and Aim: Few studies compared endoscopic ultrasound (EUS)-guided fine needle aspiration (EUS-FNA) with endoscopic retrograde cholangiopancreatography (ERCP)-based tissue sampling in terms of diagnostic accuracy in suspected malignant biliary obstruction. We evaluated and compared the diagnostic performance of EUS-FNA and ERCP-based tissue sampling. Methods: This multicenter study included 263 patients with suspected malignant biliary obstruction who underwent same-session EUS and ERCP between 2012 and 2016. Results: Malignancies were confirmed in 239 patients (90.9%) and benign in 24 patients (9.1%). Overall diagnostic sensitivity and accuracy were 73.6% and 76.1% for EUS-FNA, 56.5% and 60.5% for ERCP, and 85.8% and 87.1% for EUS/ERCP combination. EUS-FNA showed higher overall performances compared with ERCP (P < 0.001), whereas EUS/ERCP combination was superior to EUS-FNA alone (P-value < 0.001). EUS-FNA showed higher sensitivity and accuracy compared with ERCP for pancreatic masses (n = 187, both P-values < 0.001) but not for biliary lesions (n = 76, both P-values = 0.847). Sensitivity and accuracy of EUS/ERCP combination were superior to those of EUS-FNA for both pancreatic and biliary lesions (both P-values < 0.001). For patients with large mass (≥ 4 cm), there was no significant differences between ERCP/EUS combination and EUS-FNA (P-value = 0.31). Conclusions: Same-session EUS-FNA and ERCP combination was superior to EUS-FNA for both pancreatic masses and biliary lesions. Same-session EUS/ERCP combination can be considered a proper diagnostic method for suspected malignant biliary obstruction regardless of the origin of lesions. On the other hand, EUS-FNA alone was sufficient for diagnosis compared with EUS/ERCP combination in cases with large mass. Strategic diagnostic approach, according to clinical features of individual patient, is required.
Introduction
Accurate diagnosis of extrahepatic biliary obstruction has been considered a challenging task for gastroenterologists. Previous studies have reported that malignancy was found at the final diagnosis in 55-95% of patients with biliary obstructions. [1] [2] [3] [4] [5] [6] Currently, two tools are available to diagnose an indeterminate biliary obstruction pathologically, namely, endoscopic retrograde cholangiopancreatography (ERCP)-based tissue sampling and endoscopic ultrasound (EUS)-guided fine needle aspiration (EUS-FNA).
Endoscopic retrograde cholangiopancreatography has conventionally been used for diagnosis, tissue acquisition, and treatment of biliary obstruction. ERCP-based tissue sampling methods, including brush cytology and intraductal forceps biopsy, have demonstrated sensitivity in only 35-75% of indeterminate biliary obstructions. 2, 4, [7] [8] [9] Although the diagnostic yield of ERCP-based tissue sampling is relatively lower than that of EUS-FNA, ERCP has the advantage of biliary obstruction treatment by balloon dilatation or stent insertion. EUS-FNA is a relatively new method of diagnosis and tissue acquisition for biliary obstruction. Various studies have reported sensitivity of 50-95% for EUS-FNA to diagnose indeterminate biliary obstruction. [2] [3] [4] [5] 10, 11 A recent metaanalysis concluded that the pulled sensitivity and specificity of EUS-FNA for malignant biliary stricture were 80% and 97%, respectively. 12 Although EUS-FNA reported a better diagnostic yield compared with ERCP-based tissue sampling, few comparative studies between EUS-FNA and ERCP-base tissue sampling in samepatient and same-session procedures have been performed. Weilert et al. reported that EUS-FNA was superior to ERCP-based tissue sampling for suspected malignant biliary obstruction, in a prospective comparative study performed within the same-session procedures. 4 However, the sensitivity and accuracy of EUS-FNA in this study seemed to be relatively high compared with those in previous studies, as EUS-FNA was supported by on-site cytological evaluation.
To confirm the results of previous studies in same-session procedures as well as to find a better tissue acquisition strategy for indeterminate biliary obstruction, we conducted this retrospective multicenter comparative study. The aim of this study was to evaluate and compare the diagnostic performance of EUS-FNA and ERCP-based tissue sampling for suspicious malignant biliary obstruction in a same-session study.
Methods
Patient selection and data. Patients with suspected malignant biliary obstruction, who underwent same-session EUS-FNA and ERCP-based tissue sampling between January 2012 and December 2016, were retrospectively included from multiple tertiary referral centers in South Korea. Data related to patient demographics, clinical findings, results of procedures, and pathological findings were collected. This study was approved by the local Institutional Review Board and was conducted in accordance with the principles set forth in the Declaration of Helsinki. The institutional review boards of all participating institutions approved this study.
Study sites. This study was performed at four tertiary referral centers in South Korea (Kyungpook National University Medical Center, Yonsei University Severance Hospital, Seoul National University Bundang Hospital, and Ulsan University Asan Medical Center). All centers have state-of-the-art endoscopy facilities, equipped with ERCP/EUS dedicated units and experienced endoscopists with advanced skills in ERCP and EUS-FNA.
Procedures and definitions. Endoscopic ultrasound and ERCP were performed by the same endoscopist during the same session. All endoscopists were highly experienced with a current volume of 500 ERCP/EUS cases per year, including 100 or more FNA, and used a well-established technique. 13 While the patients were under conscious sedation, linear echoendoscope was inserted orally, and the lesion was punctured with various sized aspiration needles, depending on the individual center. Targets of EUS-FNA were mass lesions of pancreas and biliary strictures with targetable mass. All procedures were performed with a linear array echoendoscope (Olympus UCT 260, Olympus Co., Tokyo, Japan). After EUS-FNA was performed, patients were moved to ERCP unit for ERCP-based tissue sampling. During ERCP, tissue acquisition was performed by using intraductal biopsy or cytology via endoscopic nasobiliary drainage or brushing at biliary tract. If needed, strictures were dilated by a balloon or biliary stent after tissue sampling. The technical failure of EUS-FNA and ERCP was defined as failure to obtain tissue for pathological examination due to technical problems such as difficulty of endoscopic approach to the lesion or the risk of hemorrhage due to a mass with a collateral vessel.
Data on various tools used in EUS and ERCP procedures for tissues acquisition, such as aspiration needle size, number of EUS needle punctures, and method of ERCP-based tissue sampling, were recorded. Tissue samples from EUS-FNA and ERCP-based sampling were sent to the pathology department of each center for interpretation by expert pathologists. On-site cytopathological evaluation was not available in all centers. Tissue samples were classified into the following categories: (i) malignant; (ii) atypical, suspicious malignant; (iii) atypical, favor benign; (iv) benign; and (v) non-diagnostic, insufficient material. Categories of "malignant" and "suspicious malignant" were considered as malignant lesions, and "favor benign" and "benign" were considered as benign lesions. If tissue acquisition failed by any technical failure by EUS-FNA or ERCP, it was considered as "non-diagnostic" by intention-to-treat analysis.
To calculate the diagnostic performance, pathologic reports of EUS-FNA and ERCP-based tissue sampling were compared with the final diagnosis. Final diagnosis was established by the following methods: (i) surgical pathology; (ii) pathologic diagnosis made by EUS or ERCP sampling with evidence for malignancy; (iii) pathologic diagnosis made by other tissue acquisition method, such as percutaneous biopsy for liver metastasis or endoscopic biopsy for direct invasion of tumor into duodenum; and (iv) clinical diagnosis by long-term follow-up of longer than 6 months. Malignant findings in follow-up imaging studies, such as presence of distant metastasis or tumor involvements to the vessel, were considered as evidence of malignancy.
Statistical analysis. Demographic and clinical data were presented as descriptive values and percentages, or as median values and ranges, as appropriate. Data were analyzed by using the χ 2 , Fisher's exact, and Student's t-tests to compare variables. Comparisons of diagnostic performance were described by sensitivity, specificity, accuracy, positive predictive value, and negative predictive value (NPV) of the diagnostic methods using a generalized estimating equation model. 14 To calculate the diagnostic performance, "positive" result of diagnostic test and final diagnosis was defined as "confirmation of malignancy" and "negative" result as "non-confirmation of malignancy," including benign and nondiagnostic. In addition, the diagnostic performance when defining non-diagnostic as malignant or benign randomly according to the proportion of final diagnosis was analyzed as supplementary. All statistical analyses were performed by using Statistical Analysis System version 9.4 (SAS Inc., Cary, NC, USA).
Results
This study evaluated 263 cases with suspicious malignant biliary obstruction undergoing same-session EUS-FNA and ERCP. Table 1 shows the demographic and clinical characteristics of included patients. The mean age of patients was 64.6 ± 10.5 years, and 167 patients (63.5%) were men. A total of 193 (73.4%) patients had jaundice at the time of initial diagnosis. The causes of biliary obstruction detected by pre-evaluation computed tomography or magnetic resonance imaging were pancreatic mass in 179 patients (68.1%), biliary mass in 76 patients (28.9%), and biliary stricture in eight patients (3.0%). For cases with biliary mass or strictures, there were five cases (6.0%) at hilum, 16 cases (19.0%) at common hepatic duct, 34 cases (40.5%) at midcommon bile duct, and 29 cases (34.5%) at distal-common bile duct (details are shown in Table S1 ).
Technical success rate of EUS-FNA was 99.2% (261/263 cases), and the mean target size was 26.9 ± 11.6 mm under EUS. The mean number of punctures for EUS-FNA was 2.7 ± 1.2, and there was no significant difference of diagnostic accuracy of EUS-FNA between 198 cases punctured less than 4 times and 65 cases punctured 4 times or more (74.7% vs 73.8%, P = 0.885). The most commonly used needle size was 22 gauge (161/263 cases, 61.2%), followed by 25 gauge (65/263 cases, 24.7%), 20 gauge (31/263 cases, 11.8%), and 19 gauge (6/263 cases, 2.3%).
Diagnostic accuracies according to needle size were 75.3% with 25 gauge, 75.1% with 22 gauge, 70.9% with 20 gauge, and 66.7% with 19 gauge. No statistically significant difference was found in diagnostic performances between patients by using different gauge of needle (P = 0.596). The information of complications of EUS-FNA and ERCP-based tissue sample is described in Table  S2 . There were two cases (0.7%) of EUS-FNA induced bleeding. There was no documented biliary leakage or bowel perforation after EUS-FNA.
Aspirated specimens were prepared into the pathologic block with cytology in 205 cases (77.9%) and were evaluated by cytology only in 58 cases (22.1%). Diagnostic accuracies were 79.3% in cytology only cases and 73.1% in pathologic block with cytology without significant difference (P = 0.343). ERCP-based tissue sampling presented a technical success rate of 97.7% (257 out of 263 cases). Intraductal biopsy was performed in most cases (246/ 257 cases, 95.7%), endoscopic nasobiliary drainage cytology in 22 cases, and cytology brushing in eight cases. The median number of intraductal biopsies was 3 (range, 1-7), and cytology brushing was performed once in all cases. After tissue sampling, biliary stents were inserted in 226 cases (85.9%). After ERCP, there were six cases (2.3%) of bleeding, two cases (0.7%) of ascending cholangitis, and 14 cases (5.3%) of post-ERCP pancreatitis (Table S2) .
Pathologic reports of samples from EUS-FNA and ERCP-based tissue sampling are presented in Table 2 . EUS-FNA resulted in 133 (50.6%) malignant cases, 48 (18.3%) suspicious malignant cases, 12 (4.6%) favor benign cases, and 24 benign cases. Other 46 cases (17.5%) were non-diagnostic. ERCP-based tissue sampling detected 102 (38.8%) malignant cases, 35 (13.3%) suspicious malignant cases, seven (2.7%) favor benign cases, and 86 benign cases. Other 33 cases (12.5%) were non-diagnostic. Tables 3 and 4 show data of the final diagnosis. Final diagnoses were established by surgical pathology (61 cases, 23.2%), pathologic diagnosis made by EUS or ERCP sampling (165 cases, 62.3%), pathologic diagnosis by other methods (10 cases, 3.8%), and long-term clinical follow-up (27 cases, 10.2%). Among patients who made final diagnosis by clinical follow-up, 13 patients were diagnosed with malignant disease and 14 patients were diagnosed with benign disease. Among 239 malignant cases, 163 (62.0%) were pancreatic cancers, followed by cholangiocarcinoma (53 cases, 20.2%), gallbladder cancer (14 cases, 5.3%), and others (malignant intraductal papillary mucinous neoplasm, malignant lymphoma, and hepatocellular carcinoma). Of 24 benign cases, the most common condition was autoimmune pancreatitis (12 cases, 4.5%), followed by masses forming chronic pancreatitis (five cases, 1.9%). Comparison of diagnostic performances of EUS-FNA and ERCP-based sampling using generalized estimating equation method is described in Table 5 . The overall sensitivity and accuracy were 73.6% and 76.1% for EUS-FNA, 56.5% and 60.5% for ERCP, and 85.8% and 87.1% for combination of EUS-FNA and ERCP-based tissue sampling (EUS/ERCP combination), respectively. The sensitivity, specificity, and NPV of EUS-FNA were significantly higher than those of ERCP-based tissue sampling (all P-values < 0.001). Comparison of performances by different diagnostic approaches, including EUS/ERCP combination, showed that EUS/ERCP combination was significantly superior to EUS-FNA in terms of sensitivity, accuracy, and NPV (all P-values < 0.001). No significant differences in specificity and positive predictive value were found between the groups. Also, comparison analyses were performed in which non-diagnostic cases do not contribute to the denominators in the NPV estimates (Table S3 ). Cases of non-diagnostic was assigned as malignant or benign randomly according to the proportion of final diagnosis to reduce effect of ratio difference of "non-diagnostics" in each methods. As results, there were also significant differences of diagnostic performances between groups in sensitivity, accuracy, and NPV (all P-values < 0.05). Table 6 shows subgroup analysis of diagnostic performance according to the origin of lesions. For pancreatic masses (n = 187), EUS-FNA was significantly superior to ERCP-based tissue sampling in terms of sensitivity and accuracy (both P-values < 0.001); however, for biliary masses or strictures (n = 76), EUS-FNA was not superior to ERCP-based tissue sampling (both P-values = 0.847).
The sensitivity and accuracy of EUS/ERCP combination were still superior to EUS-FNA and ERCP-based tissue sampling for pancreatic masses and biliary masses or strictures, respectively (both P-values < 0.001). Table 7 shows another subgroup analysis according to target size. For patients with mass sized 4 cm or more, there was no significant difference in diagnostic performances between ERCP/EUS combination and EUS-FNA alone groups in sensitivity, accuracy, and NPV (P-value = 0.309, 0.311, and 0.308 for each). For mass smaller than 4 cm, using EUS/ERCP combination was still superior to using EUS-FNA alone in diagnostic performance (all P-values < 0.0001). For patients with mass sized 3.5 cm or more, EUS/ERCP combination was superior to EUS-FNA alone in sensitivity and accuracy (P-value = 0.0381 and 0.0388) but not in NPV (P = 0.0592). For mass smaller than 3.5 cm or without jaundice, EUS/ERCP combination was superior to EUS-FNA alone (all P-values < 0.0001).
Discussion
In this study, we presented retrospective multicenter data of EUS-FNA and ERCP-based tissue sampling for suspicious malignant biliary obstruction during the same session. In comparing the diagnostic performance of these techniques, EUS-FNA showed significantly higher overall sensitivity and accuracy for the diagnosis of malignant biliary obstruction. In subgroup analysis, EUS-FNA showed superior diagnostic performances compared with ERCPbased tissue sampling in patients with pancreatic masses; however, EUS-FNA was not superior in patients with biliary masses or strictures. When comparing EUS-FNA with EUS/ERCP combination, EUS/ERCP combination presented superior overall diagnostic performances regardless of the origin of mass. On the other hand, EUS-FNA alone showed non-inferior diagnostic performance compared with EUS/ERCP combination in mass size-based subgroup analysis.
A few previous studies compared the diagnostic performances of EUS-FNA and ERCP-based tissue sampling for biliary obstruction. A prospective study on 51 patients reported that EUS-FNA was superior to ERCP-based tissue sampling for the diagnosis of suspected malignant biliary obstruction. 4 The authors reported overall sensitivity and accuracy of 94% and 94% for EUS-FNA and 50% and 53% for ERCP sampling, respectively. Sensitivity of EUS-FNA was extremely high due to on-site cytological evaluation. According to a recent meta-analysis on the diagnostic yield of EUS-FNA for malignant biliary stricture, pooled sensitivity and specificity of EUS-FNA were 80% and 97%, respectively. 12 Another meta-analysis on EUS-FNA versus ERCP-based tissue sampling reported that the mean sensitivities of ERCP and EUS-FNA for tissue diagnosis of malignant biliary stricture were 49% and 75%, respectively. 15 In other words, previous studies reported sensitivity and accuracy of EUS-FNA ranging from 65% to 80%, including the results for studies without the support of on-site cytological evaluation, which was similar to our results.
Previous comparative studies of EUS-FNA and ERCP-based tissue sampling in suspected biliary obstruction reported that EUS-FNA was superior for pancreatic masses and found no difference between the two methods for biliary stricture or masses. 2, 4 These results are similar to those obtained in our study, and this seems to be a natural conclusion, as EUS is advantageous in terms of approach to pancreatic masses and ERCP is easier to access for biliary lesions, especially biliary strictures. However, our further analysis of EUS/ERCP combination showed that addition of ERCP-based sampling to a pancreatic mass was superior to that of EUS alone and that the addition of EUS-FNA to biliary stricture further enhanced diagnostic performance. Accurate diagnosis of suspected malignant biliary obstruction is a challenging task for endoscopists. Currently, ERCP-based tissue sampling and EUS-FNA are widely available; however, their diagnostic accuracy is limited. Rapid on-site cytological evaluation (ROSE) is a technique for improving the diagnostic accuracy of EUS-FNA. A study on ROSE of EUS-FNA reported that the diagnostic accuracy of EUS-FNA with ROSE was significantly superior to EUS-FNA only, with an accuracy of 97.7% versus 64.8%, respectively (P = 0.001). 16 Another study reported that, compared with EUS-FNA alone, ROSE could increase the diagnostic accuracy of EUS-FNA from 69.2% to 91.8%. 17 However, it is not easy to implement ROSE or mutation analyses at all endoscopic centers, due to the problems of manpower and costs. In this study, we suggest a same-session approach of EUS-FNA and ERCP-based tissue sampling as a more accessible method to improve the diagnostic performance.
Endoscopic retrograde cholangiopancreatography-based tissue sampling requires almost no additional cost compared with ROSE, which requires labor costs for on-site pathologists. ERCP is usually performed after EUS-FNA for treatment of biliary obstruction, even if EUS-FNA has been successfully performed for diagnosis. Moreover, jaundice was present in 73.4% of patients in our study, and biliary stent was inserted in 85.9% of patients, although the technical success rate of EUS-FNA was 99.2%. A significant increase in diagnosis rate can be obtained by adding intraductal biopsy at the time of ERCP stenting, regardless of the origin of lesions. Therefore, same-session EUS-FNA and ERCP-based tissue sampling should be considered for patients with suspected malignant biliary obstruction, in order to increase the accuracy of their diagnosis.
In this study, we described another subgroup that did not need additional ERCP-based tissue sampling to improve diagnostic performance of EUS-FNA alone. According to subgroup analysis based on target size, no significant differences were found in diagnostic performance between EUS-FNA alone and EUS/ERCP combination in patients with mass sized 4 cm or more. This result suggests that larger tumor size increases the success rate of EUS-FNA, thereby lowering the gain from additional ERCP-based tissue sampling. In other words, although EUS/ERCP combination offers superior diagnostic performance compared with performing individual test alone, EUS-FNA alone can be enough in selected cases. Finding conditions for obtaining sufficient results with the current EUS-FNA alone may contribute to strategic approach for the diagnosis of suspicious malignant biliary obstruction. Our study had several limitations. First, this was a retrospective study. However, to our best knowledge, this study is the largest comparative study on same-session EUS-FNA and ERCP-based tissue sampling for suspected malignant biliary obstruction. Previous direct comparative studies were performed on a small number of patients, and our study population was larger than those of previous studies. [2] [3] [4] Second, the sensitivity and accuracy of EUS-FNA were relatively lower than those reported by previous studies. The mean number of EUS-FNA puncture was lower than 4 times, which recommended by previous studies, and this is a possible cause of low diagnostic performance of EUS-FNA in our study. However, there was no significant difference of diagnostic accuracy according to the number of punctures. Moreover, our results were comparable with the results of a recent metaanalysis including the researches using ROSE, although on-site cytological evaluation was not available in our study. 12 
Conclusion
In conclusion, the diagnostic performance of EUS-FNA was found to be superior compared with that of ERCP in evaluating suspected malignant biliary obstruction, particularly for pancreatic masses. However, same-session EUS/ERCP combination was superior to EUS-FNA alone for both of pancreatic masses and biliary masses or strictures. Therefore, same-session EUS/ERCP combination can be considered a proper diagnostic method for suspected malignant biliary obstruction regardless of the origin of lesions. On the other hand, EUS-FNA alone was sufficient for diagnosis compared with EUS/ERCP combination in the subgroup with tumor sizes of 4 cm or more. Efforts to improve the performance of EUS-FNA are necessary, and it is also important to find predisposing conditions that can improve the result of current techniques. Strategic diagnostic approach, according to the clinical features of individual patient, is required in the future. Tissue sampling in biliary obstruction JH Jo et al.
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